# Critique: finding-2

- Target Side: side_a
- Target Claim IDs: side_a-claim-1, side_a-claim-2
- Attack Type: evidence_gap
- Severity: high

## Claim Under Attack
A staged, reversible pricing change is the strongest recommendation under partial market data; the main decision criterion should be downside control and learning velocity rather than price optimization.

## Evidence Or Reason
The artifact assumes without evidence that a staged rollout is lower-risk than maintaining the status quo. Under partial data, the current price may already be significantly misaligned — either too low (leaving revenue on the table daily) or too high (silently bleeding prospects who never enter the pipeline). The recommendation treats 'do a small test' as inherently safe, but a slow, narrow test carries its own costs: delayed revenue capture if underpriced, continued competitive exposure, internal resource burn on instrumentation, and the risk that a small-segment test produces non-generalizable results due to segment selection bias. The artifact lists six critical unknowns yet never weighs the cost of inaction against those unknowns — it implicitly treats the current price as a neutral baseline when partial data means that assumption is exactly as unsupported as any proposed change. A decision-useful strategy under uncertainty should explicitly compare the expected cost of a wrong move against the expected cost of delayed action, not default to conservatism as though caution is free.

